These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15746476)

  • 41. Does cotrimoxazole taken by HIV-infected individuals reduce mortality among HIV-uninfected family members? Data may not support conclusion.
    van der Loeff MF; Smith PG
    AIDS; 2006 Apr; 20(7):1081-2; author reply 1081. PubMed ID: 16603867
    [No Abstract]   [Full Text] [Related]  

  • 42. New designs for clinical trials.
    Mélot C
    Crit Care Med; 2009 Jan; 37(1 Suppl):S59-64. PubMed ID: 19104226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Types of urethral catheters for management of short-term voiding problems in hospitalized adults: a short version Cochrane review.
    Schumm K; Lam TB
    Neurourol Urodyn; 2008; 27(8):738-46. PubMed ID: 18951451
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Bayesian inference of P(π1 > π2) for two proportions.
    Kawasaki Y; Miyaoka E
    J Biopharm Stat; 2012; 22(3):425-37. PubMed ID: 22416833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis.
    Berry DA
    Clin Trials; 2005; 2(4):295-300; discussion 301-4, 364-78. PubMed ID: 16281428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach.
    Yi J; Fang L; Su Z
    Contemp Clin Trials; 2012 Jan; 33(1):138-42. PubMed ID: 21983624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.
    Gamalo MA; Tiwari RC; LaVange LM
    Pharm Stat; 2014; 13(1):25-40. PubMed ID: 23913880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The sample size for a clinical trial: a Bayesian-decision theoretic approach.
    Halpern J; Brown BW; Hornberger J
    Stat Med; 2001 Mar; 20(6):841-58. PubMed ID: 11252007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Life promises and 'failed' family ties: expectations and disappointment within a clinical trial (Ivory Coast).
    Marcis FL
    Anthropol Med; 2015 Dec; 22(3):295-308. PubMed ID: 26361643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.
    Rufibach K; Jordan P; Abt M
    J Biopharm Stat; 2016; 26(2):191-201. PubMed ID: 25372950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer.
    Bloomquist E; Jin S; Zhou J; Tang S; Sridhara R
    Ther Innov Regul Sci; 2020 Jul; 54(4):861-869. PubMed ID: 32557307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparison of Bayesian interim analysis and classical interim analysis in group sequential design].
    Yuan L; Zhan Z; Tan X
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Nov; 35(11):1638-42. PubMed ID: 26607091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A structured framework for adaptively incorporating external evidence in sequentially monitored clinical trials.
    Kwiatkowski E; Andraca-Carrera E; Soukup M; Psioda MA
    J Biopharm Stat; 2022 May; 32(3):474-495. PubMed ID: 35797378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Halt to microbicide trial sets back AIDS research.
    Moszynski P
    BMJ; 2007 Feb; 334(7588):276. PubMed ID: 17297700
    [No Abstract]   [Full Text] [Related]  

  • 55. Prospective application of Bayesian monitoring and analysis in an "open" randomized clinical trial.
    Vail A; Hornbuckle J; Spiegelhalter DJ; Thornton JG
    Stat Med; 2001 Dec; 20(24):3777-87. PubMed ID: 11782033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A developing country response to Lavery et al. "In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?".
    Wassenaar DR; Ramjee G
    BMC Med Ethics; 2009 Sep; 10():16. PubMed ID: 19788765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stopping trials early for benefit: too good to be true.
    Lancet; 2008 Apr; 371(9621):1310. PubMed ID: 18424306
    [No Abstract]   [Full Text] [Related]  

  • 58. Bayesian stopping rules for trials.
    Kulvichit K
    Lancet; 2002 Jan; 359(9300):77. PubMed ID: 11809215
    [No Abstract]   [Full Text] [Related]  

  • 59. Bayesian stopping rules for trials.
    Nicholl J; Goodacre S
    Lancet; 2002 Jan; 359(9300):76-7. PubMed ID: 11809213
    [No Abstract]   [Full Text] [Related]  

  • 60. Stopping a clinical trial early because of toxicity: the Bayesian approach.
    Bring J
    Control Clin Trials; 1995 Apr; 16(2):131-2. PubMed ID: 7789136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.